

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

DISCLOSEABLE TRANSACTION

EXTENSION OF LONG STOP DATE IN RELATION TO THE INVESTMENT AND COOPERATION AGREEMENT

Reference is made to the announcement of Genscript Biotech Corporation (the “**Company**”) dated 6 April 2016 (the “**Announcement**”) in relation to the proposed investment and acquisition of 51% equity interest in Jinan Nornoon Biological Engineering Co., Ltd* (濟南諾能生物工程有限公可) (the “**Target Company**”) by way of capital injection. Unless otherwise defined, all capitalized terms used herein shall have the same meanings as defined in the Announcement.

As disclosed in the Announcement, the Completion is conditional upon the satisfaction and/or waiver of the conditions precedent under the Investment and Cooperation Agreement on or before 18 May 2016 (the “**Long Stop Date**”).

As additional time is required for the fulfillment of certain conditions precedent, including obtaining the necessary approval from the relevant governmental authorities, on 18 May 2016, Nanjing Bestzyme, the Target Company, Mr. Guo and Mr. Han (the “**Parties**”) have entered into a supplemental agreement for the purposes of extending the Long Stop Date to 30 June 2016 (or such later date as the Parties may agree). Save and except for the aforesaid extension of the Long Stop Date, all other terms of the Investment and Cooperation Agreement remain unchanged and in full force and effect.

By Order of the Board
Genscript Biotech Corporation
Dr. Zhang Fangliang
Chairman

Hong Kong, 18 May 2016

As at the date of this announcement, our executive Directors are Dr. ZHANG Fangliang, Ms. WANG Ye, and Mr. MENG Jiange; our non-executive Directors are Dr. WANG Luquan, Mr. HUANG Zuie-Chin, and Mr. PAN Yuexin; and our independent non-executive Directors are Mr. GUO Hongxin, Mr. DAI Zumian and Ms. ZHANG Min.

** for identification purposes only*